Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Join | Sign in
Home>Resources>Webcasts>This Webcast
  Webcasts
A Single-tube Assay for Detecting ALK, ROS1 and RET Fusions in Lung Cancer
Maruja Lira, Pfizer Inc, speaking at Point-of-Care Diagnostics World Congress 2013.
Date Posted: Thursday, November 14, 2013
Access to this article and other content is for registered users.

Join the Technology Networks Community

  • Access to the latest scientific news, products and research through Technology Networks
  • Upload and share your posters on ePosters
  • View a library of 1,800+ scientific and medical posters
  • A library of 3,000+ scientific videos on LabTube


Sign In



Forgotten your details? Click Here
If you already have an account with Technology Networks, please use your existing login details. If you do not yet have an account please join here.

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Related Content

Merck and Pfizer Finalize Agreement to Co-Promote XALKORI®
Co-promotion of XALKORI allows the alliance between Merck KGaA, Darmstadt, Germany, and Pfizer to establish a combined oncology sales organization in key markets for the program.
Thursday, April 09, 2015
Pfizer to Acquire Hospira for $17B
Companies have into a definitive merger agreement under which Pfizer will acquire Hospira for $90 a share in cash for a total enterprise value of approximately $17 billion.
Thursday, February 05, 2015
Pfizer Acquires Redvax
Acquisition provides Pfizer with a preclinical CMV vaccine candidate.
Thursday, January 08, 2015
Pfizer Expands Rare Disease Research with Establishment of Gene Therapy Platform
Signs collaboration with Spark Therapeutics to advance phase 1/2 Adeno-associated virus (AAV) vector program in hemophilia B.
Friday, December 12, 2014
Pfizer, Merck to Evaluate Novel Anti-Cancer Combination Regimen
This multi-center, open-label clinical study will be conducted by Pfizer and is expected to begin in 2015.
Wednesday, August 27, 2014
Pfizer to Acquire InnoPharma
Under the terms of the agreement, Pfizer will acquire InnoPharma for an upfront cash payment of $225 million, with up to $135 million of contingent milestone payments.
Wednesday, July 16, 2014
Pfizer Confirms Interest in AstraZeneca
Pfizer submitted a preliminary, non-binding indication of interest to the board of directors of AZ in January 2014 regarding a possible merger transaction.
Monday, April 28, 2014
Pfizer Announces Plan for Split-Off of Zoetis
The offer better positions Pfizer to focus on its core business as an innovative biopharmaceutical company.
Thursday, May 23, 2013
Pfizer Presents Phase 3 Safety And Immunogenicity Data On HIV Drug
Pfizer Inc. presented the results from a Phase 3 study demonstrating the immunogenicity, tolerability and safety of Prevnar 13® in adults infected with HIV.
Tuesday, March 05, 2013
Pfizer Announces Resolutions with DOJ and SEC Related to Certain International Operations
U.S. agencies praise Company’s cooperation and compliance program.
Thursday, August 09, 2012
Pfizer Announces Positive Results From Phase 3 Cancer Study
Study PROFILE 1007 evaluates XALKORI® (crizotinib) in previously treated patients with ALK-positive advanced non-small cell lung cancer.
Wednesday, June 27, 2012
Pfizer Maneuvers to Protect Lipitor from Generics
Lipitor is so valuable that Pfizer is practically paying people to keep taking its blockbuster cholesterol medicine after generic competition hit the U.S. market last week.
Tuesday, December 06, 2011
Pfizer to Acquire Icagen
Pfizer Inc. and Icagen, Inc. announce that they have entered into a definitive merger agreement.
Thursday, August 04, 2011
Pfizer and Samsung Medical Center Collaborate on Liver Cancer
Collaboration aims to conduct joint research to identify genomic mechanisms responsible for clinical outcomes in hepatocellular carcinoma.
Friday, July 16, 2010
Pfizer Joins Open-Access Medicinal Chemistry Public-Private Collaboration
Company joins the SGC-led public-private collaboration to generate small molecule inhibitors for proteins involved in epigenetic signalling.
Tuesday, June 15, 2010
Scientific News
How To Identify Drugs That Work Best For Each Patient
Implantable device could allow doctors to test cancer drugs in patients before prescribing chemotherapy.
Unique Insight into the Function of a Key Muscle Protein
In a muscle every protein has to pull its weight. Thanks to high-resolution structural analysis the role of the essential muscle protein a-Actinin is now better understood.
Gene-Editing Technique Offers Hope For Hereditary Diseases
Salk scientists use molecular "scissors" to eliminate mitochondrial mutations in eggs and embryos.
Promising Stem Cell Therapy
Animal model of breast-to-brain cancer spread allows testing of therapeutic-cell approach.
Gene Editing Corrects Mutation In Cystic Fibrosis
Yale researchers successfully corrected the most common mutation in the gene that causes cystic fibrosis, a lethal genetic disorder.
Hundreds Of Cancer Possibilities Arise From Common Skin Mole Mutation
A Houston Methodist-led team of international scientists has identified hundreds of possible new genes in mice that could transform benign skin growths into deadly melanomas.
Tapeworm Drug Shows Promise Against MRSA
A new study shows that a drug already approved to fight tapeworms in people, effectively treated MRSA superbugs in lab cultures and in infected nematode worms.
First Liquid Nanolaser Developed
Technology could lead to new way of doing ‘lab on a chip’ medical diagnostics.
Tiny Lab Devices Could Attack Huge Problem of Drug-Resistant Infections
NIH-funded project aims for fast identification and destruction of deadly bacteria.
Finding Points To A Cause Of Chronic Lung Disease
New research explains how macrophages in the lung sometimes stick around too long, even after clearing a viral infection, leading to long-term lung problems.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters